Last reviewed · How we verify
NCT06779344
MxA and CRP-Guided Use of Antimicrobial Agents for AECOPD
NA trial testing MxA and CRP tests in Acute Exacerbation Chronic Obstructive Pulmonary Disease in 458 participants. Not yet recruiting.
31 December 2026
Quick facts
| Lead sponsor | Capital Medical University |
|---|---|
| Phase | NA |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | treatment |
| Enrollment | 458 |
| Start date | 13 January 2025 |
| Primary completion | 31 December 2026 |
| Estimated completion | 31 December 2026 |
| Sites | 1 location across China |
Drugs / interventions tested
- MxA and CRP tests
- MxA and CRP feedback
- Follow up
Conditions studied
- Acute Exacerbation Chronic Obstructive Pulmonary Disease — all drugs for Acute Exacerbation Chronic Obstructive Pulmonary Disease →
Sponsor
Capital Medical University
Who can join
18 and older, any sex, with Acute Exacerbation Chronic Obstructive Pulmonary Disease. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This randomized controlled trial will investigate the clinical impact of Myxovirus Resistance A (MxA) and C-Reactive Protein (CRP)-guided antimicrobial treatment compared to usual care in outpatients with acute exacerbations of chronic obstructive pulmonary disease (AECOPD).
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06779344
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Capital Medical University trials
Trials by the same sponsor.
- NCT07379437 — Haematococcus Pluvialis Astaxanthin for Brain Aging · NA · not yet recruiting
- NCT07531394 — Safety and Efficacy of Remote Ischemic Conditioning in Patients With Acute Myocardial Injury Following Acute Ischemic St · Phase 3 · not yet recruiting
- NCT07509645 — Efficacy and Safety of Interleukin-6 Receptor Inhibitor Combined With Endovascular Treatment in Patients With Acute Post · Phase 3 · recruiting
- NCT07513233 — Anisodine Hydrobromide for Patients With Acute Ischemic Stroke Undergoing Endovascular Therapy (HEAL) · Phase 1 · not yet recruiting
- NCT07495358 — Development and Usability Evaluation of a Knowledge Graph-Based Symptom Management System for Patients With Breast Cance · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06779344 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Capital Medical University
- Last refreshed: 16 January 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06779344.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing